TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes b-cell lymphomagenesis

Pilar M. Dominguez, Hussein Ghamlouch, Wojciech Rosikiewicz, Parveen Kumar, Wendy Béguelin, Lorena Fontán, Martín A. Rivas, Patrycja Pawlikowska, Marine Armand, Enguerran Mouly, Miguel Torres-Martin, Ashley S. Doane, María T. Calvo Fernandez, Matt Durant, Veronique Della-Valle, Matt Teater, Luisa Cimmino, Nathalie Droin, Saber Tadros, Samaneh MotanaghAlan H. Shih, Mark A. Rubin, Wayne Tam, Iannis Aifantis, Ross L. Levine, Olivier Elemento, Giorgio Inghirami, Michael R. Green, Maria Figueroa, Olivier A. Bernard, Said Aoufouchi, Sheng Li, Rita Shaknovich, Ari M. Melnick

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

TET2 somatic mutations occur in ∼10% of diffuse large B-cell lymphomas (DLBCL) but are of unknown significance. Herein, we show that TET2 is required for the humoral immune response and is a DLBCL tumor suppressor. TET2 loss of function disrupts transit of B cells through germinal centers (GC), causing GC hyperplasia, impaired class switch recombination, blockade of plasma cell differentiation, and a preneoplastic phenotype. TET2 loss was linked to focal loss of enhancer hydroxymethylation and transcriptional repression of genes that mediate GC exit, such as PRDM1. Notably, these enhancers and genes are also repressed in CREBBP-mutant DLBCLs. Accordingly, TET2 mutation in patients yields a CREBBP-mutant gene-expression signature, CREBBP and TET2 mutations are generally mutually exclusive, and hydroxymethylation loss caused by TET2 deficiency impairs enhancer H3K27 acetylation. Hence, TET2 plays a critical role in the GC reaction, and its loss of function results in lymphomagenesis through failure to activate genes linked to GC exit signals. SIGNIFICANCE: We show that TET2 is required for exit of the GC, B-cell differentiation, and is a tumor suppressor for mature B cells. Loss of TET2 phenocopies CREBBP somatic mutation. These results advocate for sequencing TET2 in patients with lymphoma and for the testing of epigenetic therapies to treat these tumors. Cancer.

Original languageEnglish (US)
Pages (from-to)1633-1653
Number of pages21
JournalCancer Discovery
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes b-cell lymphomagenesis'. Together they form a unique fingerprint.

  • Cite this

    Dominguez, P. M., Ghamlouch, H., Rosikiewicz, W., Kumar, P., Béguelin, W., Fontán, L., Rivas, M. A., Pawlikowska, P., Armand, M., Mouly, E., Torres-Martin, M., Doane, A. S., Calvo Fernandez, M. T., Durant, M., Della-Valle, V., Teater, M., Cimmino, L., Droin, N., Tadros, S., ... Melnick, A. M. (2018). TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes b-cell lymphomagenesis. Cancer Discovery, 8(12), 1633-1653. https://doi.org/10.1158/2159-8290.CD-18-0657